ProgramsView all programs
From the news
- Chancellor Amma Addresses the Parliament of World’s Religions
- Amrita Students Qualify for the European Mars Rover Challenge
Publication Type : Journal Article
Thematic Areas : Medical Sciences
Publisher : Asian Journal of Pharmaceutical and Clinical Research, Innovare Academics Sciences Pvt. Ltd
Source : Asian Journal of Pharmaceutical and Clinical Research, Innovare Academics Sciences Pvt. Ltd, Volume 10, Number 10, p.10-12 (2017)
Campus : Kochi
School : School of Medicine, School of Pharmacy
Department : Nursing
Year : 2017
Abstract : Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease is found to occur only in lt;1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m2 that is 80 mg IV. The causality of the event in our case was assessed using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.
Cite this Research Publication : R. Antony, Krishna, S., James, J., Kunoor, A., and Vijayan, M., “Case report on docetaxel-induced interstitial lung disease”, Asian Journal of Pharmaceutical and Clinical Research, vol. 10, pp. 10-12, 2017.